^
Association details:
Biomarker:EGFR M766Q
Cancer:Lung Adenocarcinoma
Drug:Tagrisso (osimertinib) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib

Excerpt:
Modeling suggested that EGFR M766Q could disrupt osimertinib binding. L858R/M766Q double-mutant cells were 12-fold more resistant to osimertinib, and more than 250-fold more resistant to erlotinib and afatinib, as compared to L858R-mutant cells. In contrast, double-mutant cells remained sensitive to neratinib and poziotinib at clinically relevant doses (concentration that inhibits 50%, 4.3 and 1.3 nM, respectively).
DOI:
10.1016/j.jtho.2019.06.015